Alexis Minouflet1,2, Khelifa Hamouchi3, Massinissa Haouchine3, Béatrice Berteaux3, Jean-Marie Sérot3, Ingrid Gyselinck3, Salif Dao4, Olivier Balédent5, Jadwiga Attier-Zmudka3,5. 1. Geriatric Department, Hospital Center, 1 avenue Michel de l'Hospital, 02321, Saint-Quentin Cedex, France. alexisminouflet@gmail.com. 2. BioFlowImage, University Hospital Center, Amiens, France. alexisminouflet@gmail.com. 3. Geriatric Department, Hospital Center, 1 avenue Michel de l'Hospital, 02321, Saint-Quentin Cedex, France. 4. Radiology, Hospital Center, Saint Quentin, France. 5. BioFlowImage, University Hospital Center, Amiens, France.
Abstract
BACKGROUND: In France, despite the known risks, the use of benzodiazepines and related (BZD) is excessive, particularly in older populations. Over the age of 70, 1 person in 2 uses BZD on a long-term basis (more than 3 years), whereas it is recommended not to exceed 12 weeks. To compensate for the numerous undesirable effects and to maintain a positive benefit-risk balance, these treatments must be very effective and improve significantly the quality of life. AIMS: This study aims to determine whether the efficacy of BZD outweighs their adverse effects in older population. METHODS: In a population of 109 patients with cognitive impairment and hospitalized in Saint-Quentin (France), we recorded the use of BZD and medical background. Neuropsychological and geriatric assessments allowed cognitive and thymic evaluation. RESULTS: In our cohort of 109 patients, 50% of the subjects were BZD + and 78% were women. Patients in the BZD + group were no longer anxious but had poorer cognitive and executive performance than controls. DISCUSSION: Long-term treatment of anxiety in patients aged 75 and over with BZD appears to be effective. The deleterious impact of BZD on cognition has been demonstrated. CONCLUSIONS: These results tend to consider non-medicinal therapies as serious alternatives to BZD for treating anxiety in the older population.
BACKGROUND: In France, despite the known risks, the use of benzodiazepines and related (BZD) is excessive, particularly in older populations. Over the age of 70, 1 person in 2 uses BZD on a long-term basis (more than 3 years), whereas it is recommended not to exceed 12 weeks. To compensate for the numerous undesirable effects and to maintain a positive benefit-risk balance, these treatments must be very effective and improve significantly the quality of life. AIMS: This study aims to determine whether the efficacy of BZD outweighs their adverse effects in older population. METHODS: In a population of 109 patients with cognitive impairment and hospitalized in Saint-Quentin (France), we recorded the use of BZD and medical background. Neuropsychological and geriatric assessments allowed cognitive and thymic evaluation. RESULTS: In our cohort of 109 patients, 50% of the subjects were BZD + and 78% were women. Patients in the BZD + group were no longer anxious but had poorer cognitive and executive performance than controls. DISCUSSION: Long-term treatment of anxiety in patients aged 75 and over with BZD appears to be effective. The deleterious impact of BZD on cognition has been demonstrated. CONCLUSIONS: These results tend to consider non-medicinal therapies as serious alternatives to BZD for treating anxiety in the older population.